Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Andrea BotticelliRoberta CaputoSimone ScagnoliSimona PisegnaMichelino De LaurentiisCurigliano GiuseppeMatteo LambertiniFrancesco PantanoAntonella PalazzoIda ParisClaudio VernieriBeatrice TedescoMarianna GiampagliaMichela PalleschiZelmira BallatoreDaniele AlesiniGiuliana D'AuriaAgnese FabbriLuigi RossiAnnarita VerrazzoRoberta ScafettaDaniele MarinelliCaterina SposettiVittoria BarberiLidia StrigariPaolo MarchettiDaniele SantiniAlessandra FabiPublished in: The oncologist (2023)
Efficacy and safety of T-DXd were confirmed in an unselected real-world population of HER2+ mBC. These results are consistent with the results of known findings, and no new safety concerns were reported.